Fast neutrons irradiation as a way to overcome feline squamous cell carcinoma radioresistance: a pilot study

«Radiation and Risk», 2022, vol. 31, No. 1, pp.115-126

DOI: 10.21870/0131-3878-2022-31-1-115-126

Authors

Rodionov M.V. – Veterinarian, C. Sc., Med. Contacts: 4 Korolev Str., Obninsk, Kaluga region, Russia, 249035. Tel.: +7 (926) 456-01-16, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Koryakin S.N. – Head of Lab., C. Sc., Biol
Saburov V.O. – Researcher
Moiseev A.S. – Engineer
Petrova Yu.V. – Head of Vet. Clinic
Ivanov S.A. – Director, MD, Prof. of RAS. A. Tsyb MRRC.
Shegay P.V. – Head of the Center for Innovative Radiological and Regenerative Technologies, C. Sc., Med.
Kaprin A.D. – General Director, Academician of RAS, MD, Prof. NMRRC.
¹ A. Tsyb MRRC, Obninsk
² NMRRC, Moscow

Abstract

For the study 4 cats with unresectable oral squamous cell carcinoma were treated with combination of neutron and electron radiations. 3 cats had T2b and one had T3b stage. The first phase of treatment was performed with 14 MeV fast neutron beam, fraction dose varied from 1.0 to 1.3 Gy, 3 fractions a week, 3-5 fractions in total; in the second phase the animals were irradiated with 10 MeV electron beam, using same fractionation, fraction dose varied from 4 Gy, up to total dose of 8-36 Gy. In the course of treatment, most cats had partial or complete anorexia, the duration of which did not exceed two days, it was well controlled by antidepressants (mirtazapinum). Visual assessment and computed tomography performed from 13 to 30 days after treatment completion demonstrated showed the significant regression of tumor volume (30-67%) in all cases. 3 out of 4 animals were alive at the time of the study, average follow-up period was 84 days, maximum follow-up period was 160 days. Radiation damage was limited to local alopecia followed by leukotrichia.

Key words
oncology, squamous cell carcinoma, head and neck, oral, feline, radiation therapy, neutrons.

References

1. Marconato L., Buchholz J., Keller M., Bettini G., Valenti P., Kaser‑Hotz B. Multimodal therapeutic approach and interdisciplinary challenge for the treatment of unresectable head and neck squamous cell carcinoma in six cats: a pilot study. Vet. Comp. Oncol., 2013, vol. 11, no. 2, pp. 101-112.

2. Hayes A.M., Adams V.J., Scase T.J., Murphy S. Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice. J. Small Anim. Pract., 2007, vol. 48, no. 7, pp. 394-399.

3. Northrup N.C., Selting K.A., Rassnick K.M., Kristal O., O’Brien M.G., Dank G., Dhaliwal R.S., Jagannatha S., Cornell K.K., Gieger T.L. Outcomes of cats with oral tumors treated with mandibulectomy: 42 cases. J. Am. Anim. Hosp. Assoc., 2006, vol. 42, no. 5, pp. 350-360.

4. Bradley R.L., MacEwen E.G., Loar A.S. Mandibular resection for removal of oral tumors in 30 dogs and 6 cats. J. Am. Vet. Med. Assoc., 1984, vol. 184, no. 4, pp. 460-463.

5. Penwick R.C., Nunamaker D.M. Rostral mandibulectomy: a treatment for oral neoplasia in the dog and cat. J. Am. Anim. Hosp. Assoc., 1987, vol. 23, no. 1, pp. 19-25.

6. Fox L.E., Rosenthal R.C., King R.R., Levine P.B., Vail D.M., Helfand S.C., MacEwen G., Perez-Soler R., Calderwood-Mays M., Kurzman I.D. Use of cis-bis-neodecanoato-trans-R, R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. Am. J. Vet. Res., 2000, vol. 61, no. 7, pp. 791-795.

7. Martinez‑Ruzafa I., Dominguez P.A., Dervisis N.G., Sarbu L., Newman R.G., Cadile C.D., Kitchell B.E. Tolerability of gemcitabine and carboplatin doublet therapy in cats with carcinomas. J. Vet. Intern. Med., 2009, vol. 23, no. 3, pp. 570-577.

8. Wiles V., Hohenhaus A., Lamb K., Zaidi B., Camps-Palau M., Leibman N. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma. J. Feline Med. Surg., 2017, vol. 19, no. 2, pp. 185-193.

9. Bregazzi V.S., LaRue S.M., Powers B.E., Fettman M.J., Ogilvie G.K., Withrow S.J. Response of feline oral squamous cell carcinoma to palliative radiation therapy. Vet. Radiol. Ultrasound, 2001, vol. 42, no. 1, pp. 77-79.

10. Sabhlok A., Ayl R. Palliative radiation therapy outcomes for cats with oral squamous cell carcinoma (1999-2005). Vet. Radiol. Ultrasound, 2014, vol. 55, no. 5, pp. 565-570.

11. Poirier V.J., Kaser‑Hotz B., Vail D.M., Straw R.C. Efficacy and toxicity of an accelerated hypofractionated radiation therapy protocol in cats with oral squamous cell carcinoma. Vet. Radiol. Ultrasound, 2013, vol. 54, no. 1, pp. 81-88.

12. Fidel J.L., Sellon R.K., Houston R.K., Wheeler B.A. A nine‑day accelerated radiation protocol for feline squamous cell carcinoma. Vet. Radiol. Ultrasound, 2007, vol. 48, no. 5, pp. 482-485.

13. Fidel J., Lyons J., Tripp C., Houston R., Wheeler B., Ruiz A. Treatment of oral squamous cell carcinoma with accelerated radiation therapy and concomitant carboplatin in cats. J. Vet. Intern. Med., 2011, vol. 25, no. 3, pp. 504-510.

14. Joiner M.C., van der Kogel A. Basic clinical radiobiology. 4th edition. London, CRC press, 2009. 375 p.

15. Gulidov I.A., Aslanidi I.P. On the state and prospects of development of remote neutron therapy. Voprosy onkologii – Oncology Issues, 2014. vol. 60. no. 4. pp. 408-412. (In Russian).

16. Laramore G.E. The use of neutrons in cancer therapy: a historical perspective through the modern era. Semin. Oncol., 1997, vol. 24, no. 6, pp. 672-685.

17. Koryakin S.N., Kaydan N.A., Isaeva E.V., Ul'yanenko L.N., Lychagin A.A., Ul'yanenko S.E. The experience of using portable Russian neutron generator for gamma-neutron therapy of domestic animals with malignant tumors. Radiatsiya i risk – Radiation and Risk, 2018, vol. 27, no. 1, pp. 94-106. (In Russian).

Full-text article (in Russian)